(Q34553826)

3 August 2017

1 reference

title

Huntington's disease: new hope for therapeutics (English)

1 reference

3 August 2017

0 references

1

C T McMurray

1 reference

3 August 2017

publication date

1 November 2001

1 reference

3 August 2017

published in

Trends in Neurosciences

1 reference

3 August 2017

volume

24

1 reference

3 August 2017

issue

11 Suppl

1 reference

3 August 2017

page(s)

S32-8

1 reference

Beyond the Qs in the polyglutamine diseases

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Neurodegeneration: diseases of the cytoskeleton?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

DNA secondary structure: a common and causative factor for expansion in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Trinucleotide expansion in haploid germ cells by gap repair

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Triplet repeats form secondary structures that escape DNA repair in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Glutamine repeats and neurodegenerative diseases: molecular aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Interaction of huntingtin-associated protein with dynactin P150Glued

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Clinical correlation of striatal 1H MRS changes in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Chronic quinolinic acid lesions in rats closely resemble Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Mitochondrial defect in Huntington's disease caudate nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease. The Huntington Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Mutant huntingtin enhances excitotoxic cell death.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Mammalian caspases: structure, activation, substrates, and functions during apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Extended polyglutamine selectively interacts with caspase-8 and -10 in nuclear aggregates

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Towards a protocol for the preparation and delivery of striatal tissue for clinical trials of transplantation in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Survival, neuronal differentiation, and fiber outgrowth of propagated human neural precursor grafts in an animal model of Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Caspase inhibition increases embryonic striatal graft survival

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

Antisense gene therapy for neurodegenerative disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0166-2236%2800%2901997-4

7 January 2021

10.1016/S0166-2236(00)01997-4

Identifiers

DOI

1 reference

3 August 2017

1 reference